Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cancer Cell

• Publication date

  2016-03-14

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ccell.2016.02.004PMID 26977880PMCID PMC4794755
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy

  2015cited by this paper
• Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

  2015cited by this paper
• Innate immune recognition of cancer.

  2015cited by this paper
• Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

  2015cited by this paper
• Epigenetic silencing of Th1 type chemokines shapes tumor immunity and immunotherapy

  2015cited by this paper
• Immune checkpoint blockade: a common denominator approach to cancer therapy.

  2015cited by this paper
• The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?

  2015cited by this paper
• Immune checkpoint combinations from mouse to man

  2015cited by this paper
• Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor

  2015cited by this paper
• Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients

  2014cited by this paper
• Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy

  2014cited by this paper
• PD-1 blockade induces responses by inhibiting adaptive immune resistance

  2014cited by this paper
• Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).

  2014cited by this paper
• Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

  2014cited by this paper
• Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

  2014cited by this paper
• Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses.

  2014cited by this paper
• T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment.

  2013cited by this paper
• Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients.

  2013cited by this paper
• Innate and adaptive immune cells in the tumor microenvironment

  2013cited by this paper
• Cetuximab-mediated tumor regression depends on innate and adaptive immune responses.

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

  2013cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.

  2012cited by this paper
• LIGHT delivery to tumors by mesenchymal stem cells mobilizes an effective antitumor immune response.

  2012cited by this paper
• Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data.

  2011cited by this paper
• Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.

  2011cited by this paper
• Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

  2011cited by this paper
• Direct and indirect roles of the LTbetaR pathway in central tolerance induction.

  2010cited by this paper
• Tumor masses support naive T cell infiltration, activation, and differentiation into effectors

  2010cited by this paper
• HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation

  2010influential reference
• Immunoregulation by tumor necrosis factor superfamily member LIGHT

  2009cited by this paper
• Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment.

  2009cited by this paper
• PD-1 and its ligands in tolerance and immunity.

  2008cited by this paper
• Orchestrating the orchestrators: chemokines in control of T cell traffic

  2008cited by this paper
• Targeting the Primary Tumor to Generate CTL for the Effective Eradication of Spontaneous Metastases1

  2007cited by this paper
• Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

  2006cited by this paper
• Monocyte/macrophage infiltration in tumors: modulators of angiogenesis

  2006cited by this paper
• Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy.

  2006cited by this paper
• Recruitment and activation of naive T cells in the islets by lymphotoxin beta receptor-dependent tertiary lymphoid structure.

  2006cited by this paper
• Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors

  2005cited by this paper
• Network communications: lymphotoxins, LIGHT, and TNF.

  2005cited by this paper
• Priming of naive T cells inside tumors leads to eradication of established tumors

  2004influential reference
• PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

  2004cited by this paper
• Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

  2003cited by this paper
• Differential regulation of CCL21 in lymphoid/nonlymphoid tissues for effectively attracting T cells to peripheral tissues.

  2003cited by this paper
• The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways.

  2002cited by this paper
• Signaling via LTβR on the lamina propria stromal cells of the gut is required for IgA production

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• The Lymphotoxin-β Receptor Induces Different Patterns of Gene Expression via Two NF-κB Pathways

  2002cited by this paper
• Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

  2002cited by this paper
• Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

  2001cited by this paper
• Development and maturation of secondary lymphoid tissues.

  1999cited by this paper
• Lymphoid neo-organogenesis: lymphotoxin's role in inflammation and development.

  1999influential reference
• Chemokines and cell migration in secondary lymphoid organs.

  1999cited by this paper
• Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

  1997cited by this paper
• Yeast surface display for screening combinatorial polypeptide libraries

  1997cited by this paper
• Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic Anergy

  1997cited by this paper
• 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization.

  1996cited by this paper
• Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity

  1994cited by this paper
• Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells

  1989cited by this paper

• Opportunities and challenges of targeting cGAS–STING in cancer

  2026cites this paper
• Emerging Molecular and Computational Biomarkers in Urothelial Carcinoma: Innovations in Diagnosis, Prognosis, and Therapeutic Response Prediction

  2026cites this paper
• Pleiotropic and multicellular roles of lymphotoxin beta receptor in solid tumor immunity and therapeutic targeting.

  2026cites this paper
• Targeting immunosuppressive network in glioblastoma: Emerging strategies to overcome immunodeficiency and enhance therapeutic efficacy

  2026cites this paper
• Continuous 3D Printing-Induced Microparticle Distribution and Application.

  2026cites this paper
• Plac1+ Tumor Cell‐Treg Interplay Supports Tumorigenesis and Progression of Head and Neck Cancer

  2025cites this paper
• Controlling T cell–tumor cell interaction with a biomimetic physical barrier for cancer immunotherapy

  2025cites this paper
• A tumor-on-a-chip for in vitro study of CAR-T cell immunotherapy in solid tumors.

  2025cites this paper
• Boosting Checkpoint Blockade Immunotherapy with T Cell Membrane Redox Homeostasis Regulation and Deep Learning Enhanced NIR‐II Imaging

  2025cites this paper
• VSIG4 Promotes Tumour‐Associated Macrophage M2 Polarization and Immune Escape in Colorectal Cancer via Fatty Acid Oxidation Pathway

  2025cites this paper
• Dual-action PD-L1 depletion in tumor cells and macrophages revitalizes immune attack in hepatocellular carcinoma

  2025cites this paper
• Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside.

  2025cites this paper
• Nanomedicine-mediated co-expression of a PD-1 blockade agent and CXCL9 synergizes T cell infiltration and activation in solid tumors.

  2025cites this paper
• A novel oncolytic Vaccinia virus armed with IL-12 augments antitumor immune responses leading to durable regression in murine models of lung cancer

  2025cites this paper
• Personalized Cancer Immunotherapy Boosted by cGAS‐STING‐Targeted Nanovaccines in Combination With Nutrient Modulation

  2025cites this paper
• Regulatory T cell and endothelial cell crosstalk

  2025cites this paper
• Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy

  2025cites this paper
• Intratumoral plasma cells predict patient prognosis and responsiveness to neoadjuvant immunotherapy in advanced gastric cancer

  2025cites this paper
• Electrochemotherapy with bleomycin, oxaliplatin, or cisplatin in mouse tumor models, from tumor ablation to in situ vaccination

  2025cites this paper
• Overcoming chimeric antigen receptor-T (CAR-T) resistance with checkpoint inhibitors: Existing methods, challenges, clinical success, and future prospects: A comprehensive review.

  2025cites this paper
• Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs

  2025cites this paper
• Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade

  2025cites this paper
• The roles of tertiary lymphoid structures in orchestrating immune responses in peripheral organs

  2025cites this paper
• Reduction of lymphotoxin beta receptor induces cellular senescence via the MDMX-p53 pathway

  2025cites this paper
• Exosomes-incorporated biomaterials boost cancer immunotherapy

  2025cites this paper
• The solid tumor microenvironment and related targeting strategies: a concise review

  2025cites this paper
• Understanding the Tumor Microenvironment and Therapy Resistance in Head and Neck Squamous Cell Carcinoma

  2025cites this paper
• Inhibition of ARH2 by pH/ROS-responsive nanosystem for improved lung adenocarcinoma immunochemotherapy

  2025cites this paper
• DNASE1L3-expressing dendritic cells promote CD8+ T cell function and anti-PD-(L)1 therapy efficacy by degrading neutrophil extracellular traps.

  2025cites this paper
• hmLIGHT Enhances Vaccine Antitumor Effects by Facilitating T-cell Infiltration and Activation in the 4T1 Breast Cancer Model.

  2025cites this paper
• Linking tumour angiogenesis and tumour immunity

  2025cites this paper
• A quantitative systems pharmacology model to inform clinical translation of dynamic PKPD relationships of engineered IL-15.

  2025cites this paper
• Immunotherapy in the Treatment of Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma

  2025cites this paper
• Nanoparticle-Mediated Toll-Like Receptor Activation and Dual Immune Checkpoint Downregulation for Potent Cancer Immunotherapy.

  2025cites this paper
• NCOA3 impairs the efficacy of anti-PD-L1 therapy via HSP90α/EZH2/CXCL9 axis in colon cancer.

  2025cites this paper
• Therapeutic vaccine strategies in cancer: advances, challenges, and future directions

  2025cites this paper
• Checkpoint inhibitor rechallenge in advanced endometrial cancer: revisiting the immune landscape beyond first-line therapy.

  2025cites this paper
• Augmenting CAR T Cell Functions with LIGHT.

  2024cites this paper
• Applications of nanotechnology in remodeling the tumour microenvironment for glioblastoma treatment.

  2024cites this paper
• Recent advances in biomimetic strategies for the immunotherapy of glioblastoma.

  2024cites this paper
• Novel insights into immune cells modulation of tumor resistance.

  2024cites this paper
• Machine learning‐based identification of a cell death‐related signature associated with prognosis and immune infiltration in glioma

  2024cites this paper
• Radiomics signature for dynamic changes of tumor-infiltrating CD8+ T cells and macrophages in cervical cancer during chemoradiotherapy

  2024cites this paper
• The multiple faces of cGAS-STING in antitumor immunity: prospects and challenges

  2024cites this paper
• IFN-α/β/IFN-γ/IL-15 pathways identify GBP1-expressing tumors with an immune-responsive phenotype

  2024cites this paper
• Nanodrug modified with engineered cell membrane targets CDKs to activate aPD-L1 immunotherapy against liver metastasis of immune-desert colon cancer.

  2024cites this paper
• A radiomics signature derived from CT imaging to predict MSI status and immunotherapy outcomes in gastric cancer: a multi-cohort study

  2024cites this paper
• Functionalization and magnetonavigation of T-lymphocytes functionalized via nanocomposite capsules targeting with electromagnetic tweezers.

  2024cites this paper
• An AI-based approach for modeling the synergy between radiotherapy and immunotherapy

  2024cites this paper
• Tertiary lymphoid structures in anticancer immunity

  2024cites this paper
• Engineered Nanomaterials for Tumor Immune Microenvironment Modulation in Cancer Immunotherapy.

  2024cites this paper
• Discovery of a Novel CSF-1R Inhibitor with Highly Improved Pharmacokinetic Profiles and Superior Efficacy in Colorectal Cancer Immunotherapy.

  2024cites this paper
• Immunotherapy combined with apatinib in the treatment of advanced or metastatic gastric/gastroesophageal tumors: a systematic review and meta-analysis

  2024cites this paper
• Clinical multi-dimensional prognostic nomogram for predicting the efficacy of immunotherapy in NSCLC

  2024cites this paper
• Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure

  2024cites this paper
• LTβR Agonism Promotes Anti-Tumor Immune Responses via Modulation of the Tumor Microenvironment.

  2024cites this paper
• Exploring potential predictive biomarkers through historical perspectives on the evolution of systemic therapies into the emergence of neoadjuvant therapy for the treatment of hepatocellular carcinoma

  2024cites this paper
• The effect of smoking on tumor immunoediting: Friend or foe?

  2024cites this paper
• Regulatory T cells crosstalk with tumor cells and endothelium through lymphotoxin signaling

  2024cites this paper
• Landscape of adenosine pathway and immune checkpoint dual blockade in NSCLC: progress in basic research and clinical application

  2024influential citation
• Tumor necrosis factor superfamily signaling: life and death in cancer

  2024cites this paper
• Cold and hot tumors: from molecular mechanisms to targeted therapy

  2024cites this paper
• Kynurenine-AhR reduces T-cell infiltration and induces a delayed T-cell immune response by suppressing the STAT1-CXCL9/CXCL10 axis in tuberculosis

  2024cites this paper
• Suppression of the METTL3-m6A-integrin β1 axis by extracellular acidification impairs T cell infiltration and antitumor activity.

  2024cites this paper
• Hybrid Cellular Nanovesicles Block PD-L1 Signal and Repolarize M2 Macrophages for Cancer Immunotherapy.

  2024cites this paper
• Immune Cell Infiltration Types as Biomarkers for the Recurrence Diagnosis and Prognosis of Bladder Cancer

  2024cites this paper
• Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer

  2024cites this paper
• Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma

  2023cites this paper
• Targeting CD47 enhanced the antitumor immunity of PD-L1 blockade in B-cell lymphoma.

  2023cites this paper
• CD200+ cytotoxic T lymphocytes in the tumor microenvironment are crucial for efficacious anti–PD-1/PD-L1 therapy

  2023cites this paper
• Role of tumor microenvironment in cancer progression and therapeutic strategy

  2023cites this paper
• Oncolytic Parapoxvirus induces Gasdermin E-mediated pyroptosis and activates antitumor immunity

  2023cites this paper
• A Novel TrxR1 Inhibitor Regulates NK and CD8+ T Cell Infiltration and Cytotoxicity, Enhancing the Efficacy of Anti-PD-1 Immunotherapy against Hepatocarcinoma.

  2023cites this paper
• A hierarchical tumor-targeting strategy for eliciting potent antitumor immunity against triple negative breast cancer.

  2023cites this paper
• Safflower Yellow Inhibits Progression of Hepatocellular Carcinoma by Modulating Immunological Tolerance via FAK Pathway

  2023cites this paper
• Immune Escape in Glioblastoma: Mechanisms of Action and Implications for Immune Checkpoint Inhibitors and CAR T-Cell Therapy

  2023cites this paper
• High-plex spatial transcriptomic profiling reveals distinct immune components and the HLA class I/DNMT3A/CD8 modulatory axis in mismatch repair-deficient endometrial cancer

  2023cites this paper
• IL12/18/21 pre-activation enhances the anti-tumor efficacy of expanded γδT cells and overcomes resistance to anti-PD-L1 treatment.

  2023cites this paper
• Challenges in developing personalized neoantigen cancer vaccines

  2023cites this paper
• Gene-activating nanomedicine for the tumor-oriented infiltration of T cells to enhance immunotherapy against solid tumors

  2023cites this paper
• 3D gradient printing based on digital light processing.

  2023cites this paper
• Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy

  2023cites this paper
• Establishment of a Seven-Gene Signature Associated with CD8+ T Cells through the Utilization of Both Single-Cell and Bulk RNA-Sequencing Techniques in Clear Cell Renal Cell Carcinoma

  2023cites this paper
• Amplifying oxidation stress and T-cell activation by bioactive layered double hydroxide sonosensitizers for enhanced cancer immunotherapy

  2023cites this paper
• Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRβ complex in hepatocellular carcinoma

  2023influential citation
• Tumors cells with mismatch repair deficiency induce hyperactivation of pyroptosis resistant to cell membrane damage but are more sensitive to co-treatment of IFN-γ and TNF-α to PANoptosis

  2023cites this paper
• Harnessing the power of oncolytic virotherapy and tertiary lymphoid structures to amplify antitumor immune responses in cancer patients.

  2023cites this paper
• Tumor and local lymphoid tissue interaction determines prognosis in high-grade serous ovarian cancer

  2023cites this paper
• Gut microbiota interactions with antitumor immunity in colorectal cancer: From understanding to application.

  2023cites this paper
• LIGHT/TNFSF14 promotes CAR-T cell trafficking and cytotoxicity through reversing immunosuppressive tumor microenvironment.

  2023cites this paper
• Breast-to-Brain Metastasis: from Microenvironment to Plasticity

  2023cites this paper
• Tertiary lymphoid structures and B lymphocytes: a promising therapeutic strategy to fight cancer

  2023cites this paper
• Late-stage MC38 tumours recapitulate features of human colorectal cancer – implications for appropriate timepoint selection in preclinical studies

  2023cites this paper
• Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma

  2023cites this paper
• Editorial: Targeting tumor vasculature to enhance cancer immunotherapy

  2023cites this paper
• Intracellular Adhesion Molecule‐1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8+ T Cells

  2023cites this paper
• DC101, an anti-VEGFR2 agent, promotes high-endothelial venule formation and immune infiltration versus SAR131675 and fruquintinib.

  2023cites this paper
• Tumor Immunophenotyping‐Derived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer

  2023cites this paper
• Comprehensive analysis of alternative polyadenylation regulators of CTLA4 and immune infiltration in clear cell renal cell carcinoma

  2023cites this paper
• The link between T cell activation and development of functionally useful tumour-associated high endothelial venules

  2023influential citation